Insight Molecular Diagnostics (IMDX) Registration Filing summary

Company overview and business model

• Focuses on molecular diagnostics, developing proprietary tests for organ transplant monitoring (VitaGraft), immunotherapy response (DetermaIO), and cancer therapy efficacy (DetermaCNI).

• Employs a decentralized model, providing test kits for hospitals, labs, and researchers, counter to the central lab model.

• Primary near-term market is organ transplant, with VitaGraft Kidney offering early detection of organ damage and positive coverage from MolDx.

• Commercializes research-use-only products and partners globally for development and distribution.

• Operates CLIA-certified labs in Tennessee and R&D in Germany, employing leading scientists.

Financial performance and metrics

• Audited financials for 2022 and 2023 are incorporated by reference, with a going concern explanatory paragraph in the 2023 audit.

• Reports ongoing operating expenses expected to increase with further test development and commercialization.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares; all proceeds go to selling stockholders.

• Will bear registration and offering expenses, while selling stockholders bear commissions and discounts.